Celltrion Inc - Company Profile
Powered by
All the data and insights you need on Celltrion Inc in one report.
- Save hours of research time and resources with
our up-to-date Celltrion Inc Strategy Report
- Understand Celltrion Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Celltrion Inc (Celltrion) is a biopharmaceutical company that focuses on the research, development, and manufacture of biosimilars and novel biopharmaceuticals. The company offers monoclonal antibodies for the treatment of rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, adult Crohn’s disease, psoriatic arthritis, and psoriasis. Its pipeline portfolio spans monoclonal antibody biosimilars for the treatment of rheumatoid arthritis; colorectal cancer; and respiratory disease; and antibody biologics and vaccines for infectious diseases such as hepatitis B, influenza, rabies, breast cancer, and seasonal influenza. Celltrion develops drugs by using its bioengineering and mammalian cell-culture technology. The company also carries out contract manufacturing of biosimilars. It has an operational presence in Korea, Russia, the UK and the US. Celltrion is headquartered in Incheon, South Korea.
Celltrion Inc premium industry data and analytics
Products and Services
Products | Services | Brands |
---|---|---|
Albothyl | - | - |
Whituben | Non-GMP Biomanufacturing Service | Truxima |
Edarbi | cGMP Biomanufacturing Service | Herzuma |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
XYZ | XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Plans/Strategy | In March, the company announced its plans to acquire Prestige Biologics. |
2024 | New Products/Services | In March, Celltrion USA launched a ZYMFENTRA (infliximab-dyyb), a subcutaneous (SC) formulation of infliximab. |
2024 | Contracts/Agreements | In January, the company signed a memorandum of understanding with WuXi XDC under which WuXi XDC will provide integrated services for antibody-drug conjugates. |
Competitor Comparison
Key Parameters | Celltrion Inc | JW Pharmaceutical Corp | Seoul Pharma Co Ltd | ChoongAng Vaccine Laboratory | Biosolution Co Ltd |
---|---|---|---|---|---|
Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
City | Incheon | Gwacheon | Cheongju | Daejeon | Seoul |
No. of Employees | 1,074 | 1,151 | 176 | 178 | 94 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
Jin Seok Seo | Chairman | Executive Board | 2021 | 39 |
Seo Jung-su | Vice Chairman | Executive Board | 2024 | - |
Woo Sung Kee | Chief Executive Officer; Director | Executive Board | 2023 | 62 |
Mincheol Shin | Head- Management Division; Director | Executive Board | 2023 | 52 |
Lee Hyeok-jae | Managing Director; Head- Product Development; Director | Executive Board | - | 48 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer